Dysfunctional Lipid‐Induced Secretion of Glucagon‐Like Peptide‐2(GLP‐2), but Not of Incretins Glucagon‐Like Peptide‐1(GLP‐1)/Glucose‐Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia

Ähnliche Einträge

• Meal‐Induced NF‐kB Activation in Mononuclear Cells Triggers Lumican Secretion and Promotes Chronic Kidney Disease in Metabolic Dysfunction‐Associated Steatotic Liver Disease
  von: Giovanni Musso, et al.
  Veröffentlicht: (2025)
• Endogenous Glucagon‐Like Peptide‐1 Receptor and Glucose‐Dependent Insulinotropic Polypeptide Receptor Signaling Inhibits Aeroallergen‐Induced Innate Airway Inflammation
  von: Shinji Toki, et al.
  Veröffentlicht: (2024)
• Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
  von: Zhimin Xu, et al.
  Veröffentlicht: (2024)
• Alcohol‐Related Liver Disease and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Molecular Pathogenesis and Therapeutic Interventions
  von: Yupin Tan, et al.
  Veröffentlicht: (2025)
• Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter Study
  von: Jing Zhao, et al.
  Veröffentlicht: (2025)